Get the Stockscreener App
8.56
4.14%
-0.37
After Hours:
8.25
-0.31
-3.62%
Personalis Inc stock is traded at $8.56, with a volume of 1.58M.
It is down -4.14% in the last 24 hours and up +15.44% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$8.93
Open:
$8.55
24h Volume:
1.58M
Relative Volume:
1.15
Market Cap:
$760.17M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-3.8044
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
-5.20%
1M Performance:
+15.44%
6M Performance:
+63.36%
1Y Performance:
+90.65%
1-Day Range:
$8.25
$8.98
1-Week Range:
$8.20
$9.50
52-Week Range:
$2.8262
$11.50
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.56 | 793.02M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
518.84 | 192.62B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
202.00 | 144.77B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
618.92 | 51.65B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
118.11 | 34.09B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
315.59 | 31.30B | 3.17B | 642.63M | 516.49M | 10.77 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Morgan Stanley Has Lowered Expectations for Personalis (NASDAQ:PSNL) Stock Price - MarketBeat
Personalis, Inc. $PSNL Stake Boosted by ARK Investment Management LLC - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Short Interest Up 21.2% in February - MarketBeat
Personalis (NASDAQ:PSNL) Shares Gap DownTime to Sell? - MarketBeat
Will Personalis Inc. outperform small cap indexesBear Alert & Free Verified High Yield Trade Plans - mfd.ru
Breaking Down Personalis: 5 Analysts Share Their Views - Sahm
Personalis, Inc. (NASDAQ:PSNL) Q4 2025 Earnings Call Transcript - Insider Monkey
Personalis (NASDAQ:PSNL) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Personalis, Inc. (PSNL) Stock Analysis: Exploring a Promising 24.98% Upside with Innovative Cancer Genomics - DirectorsTalk Interviews
Personalis (NASDAQ:PSNL) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat
Personalis, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham raises Personalis stock price target on reimbursement wins - Investing.com Nigeria
Needham raises Personalis stock price target on reimbursement wins By Investing.com - Investing.com South Africa
Personalis stock price target reaffirmed at $13 by BTIG on MRD growth - Investing.com South Africa
Personalis Q4 Earnings Call Highlights - MarketBeat
Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust C - GuruFocus
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights - BioSpace
Personalis (NASDAQ:PSNL) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Personalis: Q4 Earnings Snapshot - theheraldreview.com
Earnings call transcript: Personalis Q4 2025 sees EPS beat but revenue miss - Investing.com
Personalis (PSNL) Offers FY26 Revenue Forecast Below Expectations - GuruFocus
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates - Nasdaq
Personalis Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Progyny Inc. (PGNY) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
[10-K] Personalis, Inc. Files Annual Report | PSNL SEC FilingForm 10-K - Stock Titan
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Earnings Breakdown: Personalis Q4 - Benzinga
Personalis (NASDAQ: PSNL) details 2025 results and 2026 growth plan - Stock Titan
Personalis, Inc. Provides Earnings Guidance for the Full Year of 2026 - marketscreener.com
Personalis: Overview of Fourth Quarter Financial Results - Bitget
[Form 4] Personalis, Inc. Insider Trading Activity - Stock Titan
Personalis (PSNL) CEO gains 33,333 performance-based stock options - Stock Titan
How Personalis Inc. stock performs in weak economyJuly 2025 Macro Moves & Entry Point Confirmation Alerts - mfd.ru
Personalis (NASDAQ:PSNL) Shares Down 4.8%Should You Sell? - MarketBeat
Aberdeen Group plc Increases Stock Position in Personalis, Inc. $PSNL - MarketBeat
Personalis (PSNL) to Release Earnings on Thursday - MarketBeat
Personalis Receives Medicare Coverage for NeXT Personal in Lung Cancer Surveillance - Clinical Lab Products
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference - BioSpace
Personalis (NASDAQ:PSNL) Trading Up 6.2%Time to Buy? - MarketBeat
Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy - MSN
Why Personalis Inc. stock could benefit from AI revolutionJuly 2025 Movers & Low Risk Growth Stock Ideas - mfd.ru
Personalis gains as VA awards work order worth up to $13.5M - MSN
Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug Mood: Is Personalis Inc showing insider buyingTrade Entry Report & Real-Time Price Movement Reports - baoquankhu1.vn
Personalis, Inc. (PSNL) Stock Analysis: Evaluating a 34.51% Upside Potential in the Diagnostics Sector - DirectorsTalk Interviews
Aug Patterns: Will Personalis Inc outperform small cap indexesJuly 2025 Volume & Capital Protection Trade Alerts - baoquankhu1.vn
Tempus Ai Acquires Over 320K Shares of Personalis - TradingView
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Why Personalis Stock Is Rising: Medicare Covers Luncg Cancer MRD Test - MSN
Personalis Data Breach Lawsuit Investigation - Claim Depot
Medicare Now Covers NeXT Personal® MRD Testing for Lung Cancer SurveillancePersonalis, Inc. - Oncodaily
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Personalis Inc Stock (PSNL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tempus AI, Inc. | 10% Owner |
Nov 25 '25 |
Buy |
10.62 |
23,600 |
250,665 |
12,918,346 |
| Tempus AI, Inc. | 10% Owner |
Dec 22 '25 |
Buy |
8.93 |
28,000 |
250,040 |
13,039,067 |
| Tempus AI, Inc. | 10% Owner |
Nov 21 '25 |
Buy |
9.40 |
26,499 |
249,190 |
12,869,521 |
| Tempus AI, Inc. | 10% Owner |
Nov 24 '25 |
Buy |
9.87 |
25,225 |
248,971 |
12,894,746 |
| Tempus AI, Inc. | 10% Owner |
Nov 19 '25 |
Buy |
8.12 |
30,645 |
248,837 |
12,814,195 |
| Tempus AI, Inc. | 10% Owner |
Nov 20 '25 |
Buy |
8.63 |
28,827 |
248,777 |
12,843,022 |
| Tempus AI, Inc. | 10% Owner |
Dec 17 '25 |
Buy |
7.86 |
31,650 |
248,769 |
12,949,996 |
| Tempus AI, Inc. | 10% Owner |
Dec 19 '25 |
Buy |
8.39 |
29,641 |
248,688 |
13,011,067 |
| Tempus AI, Inc. | 10% Owner |
Dec 18 '25 |
Buy |
7.91 |
31,430 |
248,611 |
12,981,426 |
| Tachibana Aaron | CFO AND COO |
Jan 22 '26 |
Option Exercise |
9.16 |
1,201 |
11,001 |
165,659 |
2.14%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):